Skip to main content
Year archive

DBV Technologies — 2022 filings

All 78 regulatory filings released by DBV Technologies (DBV) in 2022, sourced directly from the official regulator.

78 Filings
2022 Period
2022 filings (78)
Filing Released Lang
DBV Technologies Announces FDA Has Lifted Partial Clinical Hold on VITESSE Phase 3 Pivotal Trial
Regulatory Filings
2022-12-23 English
DBV Technologies annonce la levée de la suspension clinique partielle par la FDA de l'étude clinique pivot de phase 3 VITESSE
Regulatory Filings
2022-12-23 French
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social au 30 Novembre 2022
Declaration of Voting Results & Voting Rights Announcements
2022-12-08 French
Monthly information regarding the total number of voting rights and total number of shares of the Company as of November 30, 2022
Declaration of Voting Results & Voting Rights Announcements
2022-12-08 English
DBV Technologies invitée à participer à une prochaine Conférence Investisseur
Report Publication Announcement
2022-11-22 French
DBV Technologies to Participate in Upcoming Investor Conference
Report Publication Announcement
2022-11-22 English
DBV Technologies présentera de nouvelles données cliniques lors de l’ACAAI 2022
Regulatory Filings
2022-11-09 French
DBV Technologies to Highlight New Clinical Data at ACAAI 2022
Investor Presentation
2022-11-09 English
DBV Technologies Reports Third Quarter Financial Results and Business Update
Interim / Quarterly Report Q3 2022
2022-11-03 English
DBV Technologies publie ses résultats financiers du troisième trimestre 2022 et fait le point sur ses activités
Interim / Quarterly Report Q3 2022
2022-11-03 French
DBV Technologies to Report Third Quarter 2022 Financial Results and Provide a Business Update
Report Publication Announcement
2022-10-31 English
DBV Technologies présente ses résultats financiers du troisième trimestre 2022 et fait le point sur ses activités
Earnings Release Q3 2022
2022-10-31 French
Monthly information regarding the total number of voting rights and total number of shares of the Company as of September 30, 2022
Declaration of Voting Results & Voting Rights Announcements
2022-10-20 English
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social au 30 septembre 2022
Declaration of Voting Results & Voting Rights Announcements
2022-10-20 French
DBV Technologies Announces Appointment of New Chair of its Audit Committee and Appointment of Daniele Guyot-Caparros to Board of Directors
Board/Management Information
2022-10-03 English
DBV Technologies annonce la nomination du nouveau Président de son Comité d’Audit et de Danièle Guyot-Caparros au Conseil d’Administration
Board/Management Information
2022-10-03 French
DBV Technologies fait le point sur l’étude clinique de phase 3 VITESSE
Regulatory Filings
2022-09-21 French
DBV Technologies Provides Clinical Update on VITESSE Phase 3 Trial
Regulatory Filings
2022-09-21 English
DBV Technologies Announces Initiation of Phase 3 Study (VITESSE) Using the Modified Viaskin Peanut Patch in Peanut -Allergic Children Ages 4 to 7 Years
Regulatory Filings
2022-09-07 English
DBV Technologies annonce le lancement de l’étude de phase 3 (VITESSE) portant sur le patch Viaskin Peanut modifié chez les enfants allergiques à l’arachide âgés de 4 à 7 ans
Earnings Release Q4 2022
2022-09-07 French
DBV Technologies to Present at Upcoming Investor Conferences
Regulatory Filings
2022-09-02 English
DBV Technologies invité à présenter lors des prochaines conférences investisseurs
Report Publication Announcement
2022-09-02 French
Rapport Financier du Premier Semestre 2022
Interim / Quarterly Report H1 2022
2022-08-01 French
DBV Technologies Reports Second Quarter 2022 Financial Results
Interim / Quarterly Report Q2 2022
2022-08-01 English
DBV Technologies publie ses résultats financiers du deuxième trimestre 2022
Interim / Quarterly Report Q2 2022
2022-08-01 French
Rapport Financier du Premier Semestre 2022
Interim / Quarterly Report H1 2022
2022-08-01 French
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
Capital/Financing Update
2022-07-27 English
Bilan semestriel du contrat de liquidité DBV Technologies avec ODDO BHF
Report Publication Announcement
2022-07-27 French
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social au 30 juin 2022
Declaration of Voting Results & Voting Rights Announcements
2022-07-20 French
Monthly information regarding the total number of voting rights and total number of shares of the Company as of June 30, 2022
Declaration of Voting Results & Voting Rights Announcements
2022-07-20 English
Franchissement de seuils et déclaration d'intention
Major Shareholding Notification
2022-06-30 French
DBV Technologies participera au prochain congrès EAACI 2022
Investor Presentation
2022-06-29 French
DBV Technologies to Participate in Upcoming EAACI 2022 Congress
Regulatory Filings
2022-06-29 English
Franchissements de seuils
Major Shareholding Notification
2022-06-20 French
Franchissements de seuils et déclaration d'intention
Director's Dealing
2022-06-17 French
DBV Technologies to Present at the JMP Securities Life Sciences Conference in New York
Regulatory Filings
2022-06-16 English
DBV Technologies invitée à présenter à la conférence JMP Securities Life Sciences à New York
Report Publication Announcement
2022-06-16 French
DBV Technologies annonce un financement par placement privé d'un montant de 194 millions de dollars américains
Share Issue/Capital Change
2022-06-09 French
DBV Technologies Announces Private Placement Financing of $194 Million
Share Issue/Capital Change
2022-06-09 English
DBV Technologies annonce les résultats positifs de l’étude de phase 3 EPITOPE menée avec Viaskin Peanut chez les enfants âgés de 1 à 3 ans allergiques à l’arachide
Earnings Release FY 2022
2022-06-07 French
DBV Technologies Announces Positive Topline Results from Phase 3 EPITOPE Trial of Viaskin Peanut in Peanut-Allergic Toddlers
Earnings Release FY 2022
2022-06-07 English
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social au 30 avril 2022
Declaration of Voting Results & Voting Rights Announcements
2022-05-17 French
Monthly information regarding the total number of voting rights and total number of shares of the Company as of April 30, 2022
Declaration of Voting Results & Voting Rights Announcements
2022-05-17 English
DBV Technologies annonce les résultats de son Assemblée générale ordinaire et extraordinaire 2022
AGM Information
2022-05-12 French
DBV Technologies Announces Results of Its 2022 Ordinary and Extraordinary General Meeting
AGM Information
2022-05-12 English
Franchissement de seuils
Major Shareholding Notification
2022-05-12 French
DBV Technologies Completes ADSs Sale of an amount of $15.3 million on Nasdaq through its At-The-Market program (ATM)
Share Issue/Capital Change
2022-05-05 English
DBV Technologies Establishes an At-The-Market (ATM) Program on Nasdaq
Share Issue/Capital Change
2022-05-02 English
DBV Technologies met en place un programme At-The-Market (ATM) sur le Nasdaq
Capital/Financing Update
2022-05-02 French
DBV Technologies Reports Recent Business Developments and First Quarter 2022 Financial Results
Earnings Release Q1 2022
2022-05-02 English
DBV Technologies fait le point sur le développement de ses activités et annonce ses résultats financiers du premier trimestre 2022
Interim / Quarterly Report Q1 2022
2022-05-02 French
Assemblée Générale Mixte du 12 mai 2022
AGM Information
2022-04-21 French
Ordinary and Extraordinary General Meeting of May 12, 2022
AGM Information
2022-04-21 English
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social au 31 mars 2022
Declaration of Voting Results & Voting Rights Announcements
2022-04-14 French
Monthly information regarding the total number of voting rights and total number of shares of the Company as of March 31, 2022
Declaration of Voting Results & Voting Rights Announcements
2022-04-14 English
DBV Technologies invitée à présenter à la 32e Oppenheimer Annual Healthcare Conference
Investor Presentation
2022-03-14 French
DBV Technologies to Present at the Oppenheimer’s 32nd Annual Healthcare Conference
Report Publication Announcement
2022-03-14 French
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social au 28 février 2022
Declaration of Voting Results & Voting Rights Announcements
2022-03-11 French
Monthly information regarding the total number of voting rights and total number of shares of the Company as of February 28, 2022
Declaration of Voting Results & Voting Rights Announcements
2022-03-11 English
DBV Technologies Publie son « Form 10-K » américain et son Document d’Enregistrement Universel 2021
Report Publication Announcement FY 2021
2022-03-09 French
DBV Technologies Announces Filing of 2021 Annual Report on Form 10-K and 2021 Universal Registration Document
Report Publication Announcement
2022-03-09 English
Document d'Enregistrement Universel 2021
Annual Report (ESEF) FY 2021
2022-03-09 French
Document d'Enregistrement Universel 2021
Annual Report (ESEF) FY 2021
2022-03-09 French
DBV Technologies annonce ses résultats financiers pour l’exercice 2021 et fait le point sur l’évolution récente de ses activités
Earnings Release FY 2021
2022-03-03 French
DBV Technologies Reports Full Year 2021 Financial Results and Recent Business Updates
Earnings Release FY 2021
2022-03-03 English
DBV Technologies to Report Full Year 2021 Financial Results and Business Updates on March 3, 2022
Earnings Release FY 2021
2022-02-24 English
DBV Technologies participera au prochain congrès de l’AAAAI 2022
Regulatory Filings
2022-02-22 French
DBV Technologies to Participate in Upcoming AAAAI 2022 Congress
Regulatory Filings
2022-02-22 English
DBV Technologies invitée à présenter à la conférence 11th Annual SVB Leerink Global Healthcare Conference
Regulatory Filings
2022-02-14 French
DBV Technologies to Present at the 11th Annual SVB Leerink Global Healthcare Conference
Report Publication Announcement
2022-02-14 English
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social au 31 janvier 2022
Declaration of Voting Results & Voting Rights Announcements
2022-02-09 French
Monthly information regarding the total number of voting rights and total number of shares of the Company as of January 31, 2022
Declaration of Voting Results & Voting Rights Announcements
2022-02-09 English
Bilan semestriel du contrat de liquidité DBV Technologies avec ODDO BHF
Regulatory Filings
2022-01-21 French
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
Capital/Financing Update
2022-01-21 English
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social au 31 décembre 2021
Declaration of Voting Results & Voting Rights Announcements
2022-01-12 French
Monthly information regarding the total number of voting rights and total number of shares of the Company as of December 31, 2021
Declaration of Voting Results & Voting Rights Announcements
2022-01-12 English
DBV Technologies invitée à présenter à la conférence H.C. Wainwright BioConnect 2022
Regulatory Filings
2022-01-07 French
DBV Technologies to Present at the H.C. Wainwright BioConnect 2022 Conference
Regulatory Filings
2022-01-07 English